NAAG Presidential Initiative Challenges in Health Care Cost, Competition and Policy Innovation Attorney General George Jepsen.

Slides:

Advertisements

Similar presentations

Project Advisory Committee Meeting 26th June 2012, New Delhi Vikash Batham CUTS International Exploring the Interplay between Business Regulation and Corporate.

Advertisements

A Panel Discussion 21 st Annual ACPU Meeting NIH Clinical Center April 26,

LESSON 7.3 Antitrust, Economic Regulation, and Competition

Developing a Playbook for Payment Reform Robert S. Galvin, MD 4 th National Pay for Performance Summit March 10, 2009.

Copyright 2012 Delmar, a part of Cengage Learning. All Rights Reserved. Chapter 12 Health Policy and Regulation.

Regulating Competition in ACOs: Present and Future Jaime King, JD, PhD ACO Workshop UC Berkeley May 8, 2015.

Japan Medical Device Market Overview Ian Clements Office of Japan U.S. Department of Commerce April 10, 2008.

STRUCTURE AND FUNCTIONS OF COMPETITION AGENCIES. GENERAL STRUCTURE OF CA CAs differ in size, structure and complexity The structure depicts power distribution.

Assessing the Value of the NHIS for Studying Changes in State Health Coverage Policies: The Case of New York Sharon K. Long John A. Graves Stephen Zuckerman.

Employer Payment Reform Workshop I January 11, 2013 Supported by Robert Wood Johnson Foundation’s Aligning Forces for Quality The Call to Action; If Not.

THE COMMONWEALTH FUND Figure 1. Barriers to Growth of Accountable Care Systems “In your view, how significant are the following barriers to growth of population-based,

THE NATIONAL INFLUENZA VACCINE SUMMIT: UPDATE Raymond A. Strikas, M.D. Immunization Services Division National Immunization Program Coordinating Center.

The FTC, Pharmaceuticals, Antitrust & IP: A Grab Bag October 23, 2008 This presentation was prepared from public sources. The views expressed herein do.

Texas Health Care Reform Coverage Institute September 26, 2007.

Macro environment analysis on pharmaceutical industry.

Adolescent Stakeholders Meeting Outline  Goals of meeting (5 min.)  Key strategies and issues (40 min.)  Venues, duration, and dates (10 min.)  Stakeholders.

Reviewing the Business Architecture of Consumer Price Statistics Ann Fitzgerald Chief Executive Speaking Points.

The Future of Medicare Advantage The Heritage Foundation September 10, 2008 James C. Capretta Fellow, Ethics and Public Policy Center

The social impact, limits and downside risks of enacting a competition law and policy within a society Hanoi, April 2004 Dr. Patrick Krauskopf, Vice-Director,

What ASCs Need to Know About Insurance Mergers Garfunkel Wild, P.C. 411 Hackensack Avenue 6 th Floor Hackensack, New Jersey

CONTEMPORARY ECONOMICS© Thomson South-Western 7.3Antitrust, Economic Regulation, and Competition  Explain the goal of U.S. antitrust laws.  Distinguish.

DAVID BALTO LAW OFFICES OF DAVID A. BALTO 1325 G Street, NW Suite 500 Washington, DC

Trade Policy Update Tricia Johnson – Canada Desk Office of the Western Hemisphere April 2011.

Chapter 8 Business-Government Relations Copyright © 2014 by The McGraw-Hill Companies, Inc. All rights reserved.McGraw-Hill/Irwin.

Simon of New York City (SoNYC) October 2009 Overview.

Environmental Scan 2015 TRENDS IN COLORADO’S HEALTH CARE MARKET AUGUST 2015.

Towards a more effective healthcare regulation system in China China Health System Study Group Harvard School of Public Health Presented by Wensheng Fan,

Health Policy Issues An Economic Perspective Copyright © 2015 Foundation of the American College of Healthcare Executives. Not for sale.

Chapter 4 The Legal and Regulatory Environment of Health Care.

HCA 497 MART Experience Tradition /hca497mart.com FOR MORE CLASSES VISIT

HCA 497 NERD Real Success HCA 497 Entire Course (Ash) FOR MORE CLASSES VISIT HCA 497 Week 1 DQ 1 U.S. Health Care System vs. Other.

An Economic Perspective

Prof. Frederick Abbott UNDP Consultant

Premiums in 2018: What to Expect

The Czech Health System – its Presence and Future

The IFPMA Code and how to set up a national self-regulation system Presentation to China/EU Pharmaceutical Industry Forum 17 May 2017, Shanghai, China.

Antitrust Review of Hospital-Physician Consolidations Antitrust Practice Group Mid-Year Luncheon February 11, 2013 This presentation was prepared from.

COMMUNITY SERVICES BLOCK GRANT

Washington Update PACT Medical Device Group March 7, 2013 Mark Leahey

Managing Antitrust Risks in

Small Business Committee

Why Does the FTC Care About NPs?

An Economic Perspective

Business-to-Business Markets and Buying Behavior

Medicaid: Big Decisions Ahead

PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.

Perspectives on Breastfeeding in New Mexico among Spanish-speaking Hispanics and Native Americans Maria D. Otero.

A.I.S.E. Cleaning and Hygiene Forum

MHA 618 Competitive Success/snaptutorial.com

Washington Update PACT Medical Device Group March 7, 2013 Mark Leahey

Aon Health Our Point of View April 2017.

IESBA Meeting New York March 12-14, 2018

Matthew A. Michela President & CEO, lifeIMAGE

Big Data, Algorithms, and Artificial Intelligence

Healthcare Delivery in the 21st Century: Catholic Health Initiatives

Developing a Playbook for Payment Reform

Private Sector Perspective: Key “Best Practices” that Strengthen Protection of Environment, Health and Safety while Facilitating Trade and Economic Development.

Healthcare Delivery in the 21st Century: Catholic Health Initiatives

Member Update January 2019.

The International Consortium for Personalised Medicine

Product Stewardship Institute Advisory Council Meeting The Lenox Hotel – Boston, MA September 14, 2012.

The 8th Annual Pharmaceutical Regulatory & Compliance Congress

A View from Washington, DC

Pharmacy – Fully Insured versus Self Funding

Public Sector Healthcare Roundtable

Health Reform: What It Means to Our Community

Corporate Program Update

Market risk and sizing for a health care benefits and management company The challenge Our client is a major player in the North American prescription.

Today’s Prescription Drug Coverage

Getting to the Results that Matter

Presentation transcript:

NAAG Presidential Initiative Challenges in Health Care Cost, Competition and Policy Innovation Attorney General George Jepsen

Goals: To help Attorneys General “unpack” complex challenges in health care marketplace. To generate broad, bipartisan discussion among key players on healthcare policy.

Focus: Keynote speeches and panel topics will focus on three main themes: 1. Cost 2. Competition 3. Innovation Purpose: To identify challenges, highlight trends and explore innovative approaches

Presenters: Keynote speakers and Panelists are being chosen for their expertise and dynamic perspectives on themes and related topics. They will include: 1. National health care leaders from industry, government, academia and public policy groups. 2. Experts in the health care field.

Planning: Meetings are underway to solicit input on topics. Invited to participate are: Healthcare industry trade associations (e.g., AHIP, AHA, AMA, PhARMA) Health insurance companies Pharmaceutical companies Hospitals Physicians Research and policy institutes (e.g., U.S. Chamber of Commerce, Bipartisan Policy Center, The Heritage Foundation, Brookings Institution, Robert Wood Johnson Foundation) Private attorneys representing healthcare industry clients Academic experts in healthcare policy, law, economics Consumer advocates Government officials (States, DOJ, FTC)

First Up: Fall Meeting, Nov Two panels of particular interest to AGs: 1. Health Care Consolidation: Antitrust Review and Enforcement Update 2. Pharmaceuticals: Issues Affecting Cost and Competition

Fall Meeting, Nov Panel 1: Health Care Consolidation: Antitrust Review and Enforcement Update 1. Insurance market concentration: Lessons learned from recent state and federal reviews of proposed insurance company mergers. 2. Hospitals & horizontal integration: The role of antitrust regulators as illustrated by recent cases. 3. Physician practices & vertical integration: Recent antitrust reviews and new approaches.

Fall Meeting, Nov Panel 2: Pharmaceuticals: Issues Affecting Cost and Competition 1. Consolidation of pharmaceutical companies –brand and generic 2. Pay for delay in manufacture of generic drugs 3. REMS (Risk Evaluation and Mitigation Strategies) as barrier to generic drug market entry

Topics Under Consideration for upcoming meetings Policy innovation at the state-level Drivers and impacts of industry consolidation Innovative approaches to control costs Prescription drug pricing Fee-for-service vs. value-based provider payment models Healthcare data transparency Future reform approaches

Plan Ahead: Winter Meeting: Washington, DC Feb. 27-March 1, 2017; Summit Meeting: New York City April 26-28, 2017; Summer Meeting: TBD June 20-22, 2017

Conclusion: Attorney General Jepsen welcomes your comments and suggestions: Potential panelists and keynote speakers; Topics of particular interest or concern;

Questions and/or Comments? Thank You Deputy Attorney General Perry Zinn Rowthorn Contact me: